by DAVID.KIEWLICH | Jul 30, 2026 | Biotech
Let’s be blunt: biotech funding in 2026 is not about great science anymore. It is about proven science. Venture capitalists are actively seeking out biotechs with existing data sets and de-risked pipelines; the days of backing a tantalizing hypothesis and a...
by DAVID.KIEWLICH | Jul 24, 2026 | Cell Therapy
The age of cell and gene therapy is here. The FDA has already approved more than 30 cell and gene therapies since 2017, and the global AAV manufacturing market is continuing to expand. Science, however, has outpaced the infrastructure. Before startups run into a...
by DAVID.KIEWLICH | Jul 23, 2026 | Biotech
The uncomfortable fact that many VCs prefer not to discuss is this: the climate-saving technology that will eventually define our industry won’t originate in a SoMa software firm. It will likely be discovered in a wet lab by scientists manipulating bacteria and...
by DAVID.KIEWLICH | Jul 17, 2026 | Biotech
Got the passion and the brilliant idea? Do you know that the odds of turning your great scientific idea into a market-ready business are pretty slim? That’s because there’s simply no good access to lab space in the biotech space. For far too long, many of our best...
by DAVID.KIEWLICH | Jul 16, 2026 | Bio-Innovators
It often feels like the journey from a scientific discovery to a real world, impactful innovation involves a multitude of hurdles and bottlenecks. The bio-innovators who are so often driven by curiosity and discovery to change the world, can become frustrated with the...
